Preclinical data have suggested that dipeptidyl peptidase-4 (DPP-4) inhibitors, a glucose-lowering treatment for diabetes, may promote metastatic progression of preexisting cancer via activation of Nrf2 in the cancer cells [71]. The gene discussed is DPP4; the disease is cancer.